A detailed history of Rtw Investments, LP transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Rtw Investments, LP holds 1,968,002 shares of RARE stock, worth $93 Million. This represents 1.74% of its overall portfolio holdings.

Number of Shares
1,968,002
Previous 3,259,927 39.63%
Holding current value
$93 Million
Previous $134 Million 18.41%
% of portfolio
1.74%
Previous 2.24%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$40.21 - $59.36 $51.9 Million - $76.7 Million
-1,291,925 Reduced 39.63%
1,968,002 $109 Million
Q2 2024

Aug 14, 2024

SELL
$37.42 - $51.61 $143 Million - $198 Million
-3,827,188 Reduced 54.0%
3,259,927 $134 Million
Q1 2024

May 15, 2024

BUY
$43.02 - $53.69 $8.61 Million - $10.7 Million
200,029 Added 2.9%
7,087,115 $331 Million
Q4 2023

Feb 14, 2024

BUY
$31.73 - $49.19 $47 Million - $72.9 Million
1,481,997 Added 27.42%
6,887,086 $329 Million
Q2 2023

Aug 14, 2023

BUY
$37.35 - $52.15 $42.4 Million - $59.1 Million
1,134,093 Added 26.55%
5,405,089 $249 Million
Q1 2023

May 15, 2023

BUY
$36.99 - $48.71 $11.2 Million - $14.8 Million
304,081 Added 7.67%
4,270,996 $171 Million
Q4 2022

Feb 14, 2023

BUY
$33.72 - $46.33 $54.2 Million - $74.4 Million
1,606,919 Added 68.09%
3,966,915 $184 Million
Q3 2022

Nov 14, 2022

BUY
$39.96 - $66.14 $39.4 Million - $65.3 Million
986,712 Added 71.85%
2,359,996 $97.7 Million
Q4 2021

Feb 14, 2022

BUY
$73.71 - $87.86 $101 Million - $121 Million
1,373,284 New
1,373,284 $115 Million

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.31B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Rtw Investments, LP Portfolio

Follow Rtw Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rtw Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Rtw Investments, LP with notifications on news.